WO2008113916A9 - Composition pharmaceutique comprenant des anticorps diriges contre l'enveloppe de herv-w - Google Patents

Composition pharmaceutique comprenant des anticorps diriges contre l'enveloppe de herv-w Download PDF

Info

Publication number
WO2008113916A9
WO2008113916A9 PCT/FR2008/000166 FR2008000166W WO2008113916A9 WO 2008113916 A9 WO2008113916 A9 WO 2008113916A9 FR 2008000166 W FR2008000166 W FR 2008000166W WO 2008113916 A9 WO2008113916 A9 WO 2008113916A9
Authority
WO
WIPO (PCT)
Prior art keywords
directed against
herv
pharmaceutical composition
envelope
composition containing
Prior art date
Application number
PCT/FR2008/000166
Other languages
English (en)
Other versions
WO2008113916A2 (fr
WO2008113916A3 (fr
Inventor
Herve Perron
Original Assignee
Geneuro Sa
Herve Perron
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geneuro Sa, Herve Perron filed Critical Geneuro Sa
Priority to EP08761866A priority Critical patent/EP2117594A2/fr
Priority to US12/449,327 priority patent/US20100074894A1/en
Publication of WO2008113916A2 publication Critical patent/WO2008113916A2/fr
Publication of WO2008113916A3 publication Critical patent/WO2008113916A3/fr
Publication of WO2008113916A9 publication Critical patent/WO2008113916A9/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne une composition pharmaceutique comprenant, à titre de principe actif, au moins un anticorps dirigé contre la protéine d'enveloppe de HERV- W, à l'exclusion de tout anticorps dirigé spécifiquement contre le site de liaison entre ladite protéine env et le récepteur hASCTl ou hASCT2.
PCT/FR2008/000166 2007-02-09 2008-02-11 Composition pharmaceutique comprenant des anticorps diriges contre l'enveloppe de herv-w WO2008113916A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP08761866A EP2117594A2 (fr) 2007-02-09 2008-02-11 Composition pharmaceutique comprenant des anticorps diriges contre l'enveloppe de herv-w
US12/449,327 US20100074894A1 (en) 2007-02-09 2008-02-11 Pharmaceutical composition containing antibodies directed against the herv-w envelope

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0700952 2007-02-09
FR0700952A FR2912314B1 (fr) 2007-02-09 2007-02-09 Composition pharmaceutique comprenant des anticorps diriges contre l'enveloppe de herv-w.

Publications (3)

Publication Number Publication Date
WO2008113916A2 WO2008113916A2 (fr) 2008-09-25
WO2008113916A3 WO2008113916A3 (fr) 2008-11-27
WO2008113916A9 true WO2008113916A9 (fr) 2009-01-22

Family

ID=38457775

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2008/000166 WO2008113916A2 (fr) 2007-02-09 2008-02-11 Composition pharmaceutique comprenant des anticorps diriges contre l'enveloppe de herv-w

Country Status (4)

Country Link
US (1) US20100074894A1 (fr)
EP (1) EP2117594A2 (fr)
FR (1) FR2912314B1 (fr)
WO (1) WO2008113916A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3211005T (pt) * 2008-07-08 2021-06-15 Geneuro Sa Utilização terapêutica de ligandos específicos nas doenças associadas a msrv
WO2012118974A2 (fr) * 2011-03-01 2012-09-07 University Of Medicine And Dentistry Of New Jersey Détection d'expression de rétrovirus endogène humain dans des cellules cancéreuses et des cellules saines
US10370417B2 (en) 2011-03-01 2019-08-06 Rutgers, The State University Of New Jersey Methods for the diagnosis of cancer through detection of human endogenous retrovirus WL (HERV-WL) envelope expression
EP2949342A1 (fr) 2014-05-28 2015-12-02 Geneuro SA Médicaments antirétroviraux ciblant un rétrovirus endogène humain
CA3000884A1 (fr) * 2015-10-05 2017-04-13 Metafora Biosystems Ligands de domaines de liaison de recepteurs destines a la detection, au diagnostic et au traitement du cancer du pancreas
JP6898925B2 (ja) 2015-11-10 2021-07-07 メディミューン，エルエルシー Ａｓｃｔ２特異的結合分子及びその使用
EP3351265A1 (fr) * 2017-01-20 2018-07-25 Geneuro SA Anticorp du herv-k enveloppe et ses utilisations

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001031021A1 (fr) * 1999-10-28 2001-05-03 Universite De Geneve Superantigene lie a la sclerose en plaques
FR2865403B1 (fr) * 2004-01-23 2009-06-12 Biomerieux Sa Composition pour le traitement d'une pathologie associee a la msrv/herv-w

Also Published As

Publication number Publication date
WO2008113916A2 (fr) 2008-09-25
FR2912314A1 (fr) 2008-08-15
FR2912314B1 (fr) 2012-08-03
WO2008113916A3 (fr) 2008-11-27
US20100074894A1 (en) 2010-03-25
EP2117594A2 (fr) 2009-11-18

Similar Documents

Publication Publication Date Title
WO2007106744A3 (fr) Anticorps anti-5t4 et leurs utilisations
WO2009070243A3 (fr) Agents et épitopes de liaison à wise
WO2009034119A8 (fr) Dérivés améliorés de l'amyline
WO2008100624A3 (fr) Anticorps contre erbb3 et leur utilisation
WO2008079995A3 (fr) Conjugué comprenant un peptide natriurétique et une région constante d'un anticorps
WO2008060705A3 (fr) Anticorps anti-dll4 et leurs procédés d'utilisation
WO2008082669A3 (fr) Conjugués polymère-facteur viii et facteur von willebrand comprenant une liaison dégradable
IL214996A (en) An isolated antibody linked to the bcma polypeptide, a pharmaceutical preparation containing it and its uses
WO2007076260A3 (fr) Agonistes de recepteur de farnesoide x
WO2008113916A3 (fr) Composition pharmaceutique comprenant des anticorps diriges contre l'enveloppe de herv-w
WO2008051942A3 (fr) Agonistes du récepteur farnésoïde x
WO2007130697A3 (fr) Anticorps anti-ephb4 et procedes qui les utilisent
IL199216A (en) Monoclonal Antibodies Against 3angptl, Pharmaceuticals Containing Them and Their Uses
WO2009052400A8 (fr) Anticorps qui se lient à la ngal des mammifères et utilisations de ceux-ci
WO2007120334A3 (fr) Méthodes et compositions de ciblage de la polyubiquitine
WO2007133290A8 (fr) Anticorps anti-ox40l et méthodes correspondantes
WO2010145792A8 (fr) Protéines bispécifiques se liant à un antigène
WO2008121767A3 (fr) Polypeptides cousus
WO2006138343A3 (fr) Compositions comprenant des variants de proteine associee au recepteur (rap) specifiques a lrp2, et utilisations correspondantes
WO2008157356A3 (fr) Formulations d'anticorps
WO2007075525A3 (fr) Combinaison de composes organiques
WO2009128963A3 (fr) Anticorps monoclonaux humains à neutralisation croisée dirigés contre sars-cov et procédés d'utilisation de ces derniers
WO2008100805A3 (fr) Anticorps anti-robo4 et utilisations de ceux-ci
NO20061346L (no) Peptider og forbindelser som binder til thrombopoietin-reseptorer
WO2007127506A8 (fr) Anticorps anti-ephrinb2 et procédés les utilisant

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08761866

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008761866

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12449327

Country of ref document: US